- Home
- VIR vs PSTX Comparison
VIR vs PSTX Comparison
Compare VIR & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- PSTX
- Stock Information
- Founded
- VIR 2016
- PSTX 2014
- Country
- VIR United States
- PSTX United States
- Employees
- VIR N/A
- PSTX N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VIR Health Care
- PSTX Health Care
- Exchange
- VIR Nasdaq
- PSTX Nasdaq
- Market Cap
- VIR 1.0B
- PSTX 909.4M
- IPO Year
- VIR 2019
- PSTX 2020
- Fundamental
- Price
- VIR $7.47
- PSTX $9.42
- Analyst Decision
- VIR Buy
- PSTX Hold
- Analyst Count
- VIR 5
- PSTX 3
- Target Price
- VIR $36.40
- PSTX $9.00
- AVG Volume (30 Days)
- VIR 1.4M
- PSTX 1.1M
- Earning Date
- VIR 02-20-2025
- PSTX 11-07-2024
- Dividend Yield
- VIR N/A
- PSTX N/A
- EPS Growth
- VIR N/A
- PSTX N/A
- EPS
- VIR N/A
- PSTX N/A
- Revenue
- VIR $78,618,000.00
- PSTX $150,858,000.00
- Revenue This Year
- VIR N/A
- PSTX $131.92
- Revenue Next Year
- VIR N/A
- PSTX N/A
- P/E Ratio
- VIR N/A
- PSTX N/A
- Revenue Growth
- VIR N/A
- PSTX 203.18
- 52 Week Low
- VIR $6.56
- PSTX $1.87
- 52 Week High
- VIR $13.09
- PSTX $9.58
- Technical
- Relative Strength Index (RSI)
- VIR 45.87
- PSTX 82.69
- Support Level
- VIR $7.15
- PSTX $9.36
- Resistance Level
- VIR $7.56
- PSTX $9.52
- Average True Range (ATR)
- VIR 0.40
- PSTX 0.10
- MACD
- VIR -0.02
- PSTX -0.23
- Stochastic Oscillator
- VIR 24.79
- PSTX 30.43
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.